To help its partners to continue offering the highest-quality care, Toshiba America Medical Systems Inc. is providing comprehensive and customized education through its recently enhanced online learning center.

VeriTeQ Corp. announced it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (NCSU). VeriTeQ will license 24 patents, which are the foundation for its U.S. Food and Drug Administration (FDA)-cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.

Medical imaging is at the forefront of diagnostics today, with imaging techniques like magnetic resonance imaging (MRI), computerized tomography (CT), scanning and nuclear magnetic resonance (NMR) increasing steeply over the last two decades. However, persisting problems of image resolution and quality still limit these techniques because of the nature of living tissue. A solution is hyperpolarization, which involves injecting the patient with substances that can increase imaging quality by following the distribution and fate of specific molecules in the body but that can be harmful or potentially toxic to the patient. A team of scientists from EPFL, CNRS, ENS and CPE Lyon and ETH Zürich has developed a new generation of hyperpolarization agents that can be used to dramatically enhance the signal intensity of imaged body tissues without presenting any danger to the patient. Their work is published in Proceedings of the National Academy of Sciences (PNAS).

The Radiological Society of North America (RSNA) has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to support research by the Quantitative Imaging Biomarkers Alliance (QIBA). This marks the fourth consecutive year that NIBIB has funded research groundwork by QIBA, following a 2013 contract for $1.25 million.

The Geneva Healthcare Suite has been proven effective by clinicians at the Douglas & Nancy Barnhart Cancer Center at Sharp Chula Vista Medical Center in managing risk for patients with cardiac devices undergoing radiation therapy.